Vertex Pharmaceuticals Quarterly Report June 2025

This document is a quarterly report (Form 10-Q) filed by Vertex Pharmaceuticals Incorporated with the U.S. Securities and Exchange Commission, covering the period ending June 30, 2025. It provides a comprehensive overview of the company's financial performance, including condensed consolidated statements of income, comprehensive income, balance sheets, shareholder equity, and cash flows. The report also details significant accounting policies, information on collaboration and licensing agreements (both in-licensed and out-licensed), and an in-depth management discussion and analysis of financial condition and results of operations. Key business updates on marketed products for cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain are provided, alongside progress reports on their pipeline of product candidates and an analysis of their liquidity and capital resources.

There are no comments yet.

Please log in to write the first comment.